

Kidney Transplant CMV Prophylaxis

For **initial** authorization:

1. Member is at least 18 years of age; AND
 2. Medication must be prescribed by or in consultation with an infectious disease specialist, hematologist, or transplant specialist; AND
 3. Member is the recipient of a kidney transplant; AND
 4. Member must be at high risk (donor CMV-seropositive and recipient CMV seronegative); AND
 5. Prescriber attests Prevymsis will be initiated within 7 days post-transplant; AND
- Tt C

References:

1. Prevymis [package insert]. County Carlow, Ireland: Merck Sharp & Dohme Corporation; June 2023.
2. Marty FM, Ljungman P, Chemaly RF, et al. Letemovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. *N Engl J Med.* 2017; 377(25):2433-44.
3. Kropweit D, McCormick D, Erb-Zohar K, et al. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letemovir in subjects with hepatic impairment. *Br J Clin Pharmacol.* 2017a;83(12):2678-2686.
4. Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. *Transplantation* 2018; 102:900.
5. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant.* 2019;33(9):e13512. doi:10.1111/ctr.13512
6. Limaye AP, Budde K, Humar A, et al. Letemovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. *JAMA.* 2023;330(1):33-42. doi:10.1001/jama.2023.9106

Effective date: 01/01/2024

Revised date: 07/05/2023